Placebo data and weighting

2 messages 2 people Latest: Jan 18, 2002

Placebo data and weighting

From: Joern Loetsch Date: January 17, 2002 technical
From: Joern Loetsch Subject: Placebo data and weighting Date: Thursday, January 17, 2002 11:15 Dear NONMEM users, I have fitted placebo data from a standard cross-over study and want to incorporat the placebo information intothe PK/PD fit of the verum data. However, the blunt incorporation of the placebo model into the PK/PD fit results in obvious nonsens. The drug effect would be negative in some subjects. The assumption that placebo behaviour would be invarate among study occasions is obviously wrong. When I introduce a weighting factor for the placebo information, the PK/PD fit works fine. However, I'm not sure whether a simple weight factor is adequate. Does anyone have a better solution for the placebo problem? Fitting placebo and active drug data together did not work, the model is probaly too complex, a reliable fit could not be obtained.Thanx in advance. J. Ltsch _______________________________________________________ Jorn Lotsch, MD pharmazentrum frankfurt, Department of Clinical Pharmacology Johann Wolfgang Geothe-University Hospital Theodor-Stern-Kai 7 D-60590 Frankfurt Germany Phone: +49-69-6301-4589 Fax: +49-69-6301-7636

Placebo data and weighting

From: Jogarao V Gobburu Date: January 18, 2002 technical
From: Gobburu, Jogarao V Subject: Placebo data and weighting Date: Friday, January 18, 2002 8:36 AM Hello, Now, I do not know anything about your drug and the population from the email. But I have some general comments to make. 1. Why do you consider that getting negative drug effect is nonsense in some individuals? It could be that they are non-responders. 2. You talk about placebo effect, what about disease progression? May be this is why in some patients, who either did not receive 'enough' drug or poor responders, the drug effect is over-shadowed by the disease progression. 3. It would benefit if you explained what 'weight' function was used and its rationale. 4. Ideally simulataneous analysis of all the data is preferred. Regards, Joga Gobburu, Pharmacometrics, CDER, FDA